Theophylline: Can This Old Drug Help COPD Patients Breathe Easier?
"A pilot study explores the potential of theophylline to improve exercise capacity in COPD patients already on combination inhaler therapy."
Chronic Obstructive Pulmonary Disease (COPD) significantly limits lung function and exercise capacity, impacting daily life even with modern inhaler treatments. Long-acting bronchodilators, a combination of anticholinergics and beta-agonists, have become the standard, yet many individuals still struggle with breathlessness and fatigue.
Theophylline, a medication used for decades, presents a potential solution. It's known to improve lung function and exercise performance, and because it's affordable and easy to administer, scientists have wondered whether the drug can help COPD patients. However, studies on theophylline's effectiveness have yielded mixed results.
A recent pilot study published in the International Journal of COPD aimed to clarify the role of theophylline. Researchers investigated whether adding theophylline to the existing treatment plans of COPD patients using combination inhalers could further enhance their exercise capacity and overall lung function. This article breaks down the study's findings, explores their implications, and discusses what they mean for people living with COPD.
Recent Evidence in COPD
A 2025 meta-analysis reported that theophylline may improve clinical outcomes during acute exacerbations of COPD without increasing adverse effects. Its authors cautioned that the evidence included few studies and may be affected by confounding, so they called for validation in well-designed, high-quality randomized controlled trials. For stable COPD, a separate 2025 review noted that it remains unclear whether adding oral theophylline to inhaled therapy increases adverse reactions.
From Diuretic to Bronchodilator
A technical guide reports that theophylline was first extracted and synthesized in 1895 and was initially used as a diuretic. Its clinical role expanded in 1922 after its bronchodilator effects were discovered, leading to its use as a primary treatment for asthma and COPD. A 2024 narrative review likewise describes its historical use for obstructive lung diseases, including asthma and COPD.
The Study: Theophylline's Impact on Exercise Capacity
The study, a randomized, double-blind, placebo-controlled trial, involved 24 COPD patients already using long-acting inhaled beta-agonists and anticholinergic bronchodilators. Participants were divided into two groups: one received theophylline, and the other received a placebo, both over four weeks.
- Exercise Capacity: The theophylline group showed a 26.1% improvement in exercise duration compared to the placebo group. While this indicates a trend, it wasn't statistically significant.
- Clinically Meaningful Improvement: Four out of ten patients on theophylline had an improvement exceeding 33% – considered the minimum clinically important difference – compared to only one in the placebo group.
- Peak Ventilation: The theophylline group experienced an 11.1% reduction in peak ventilation, which could suggest improved gas exchange efficiency during exercise.
- Lung Function & Breathlessness: No significant differences were observed in resting lung function or measures of dyspnea (breathlessness) between the two groups.
Exercise Capacity and Air Trapping
A review of ways to increase exercise capacity and physical activity in COPD notes that studies have tested theophylline added to long-acting bronchodilator therapy. Other sources report that theophylline may reduce air trapping in COPD. One review also says it may improve exercise performance, while emphasizing that the effects are small.
Mixed Exercise-Capacity Findings
Evidence on theophylline’s effect on exercise capacity in COPD has not been consistent. The McKay and Tsukino studies reported significant results despite enrolling only 20 and 21 patients, respectively. Other studies cited in the pilot-study report found no effect of theophylline on exercise capacity.
Alternatives to Theophylline
A clinical advice article identifies long-acting muscarinic antagonists (LAMAs) and long-acting beta agonists (LABAs) as preferred alternatives to theophylline for asthma and COPD. It says current guidelines recommend against theophylline as maintenance therapy, citing its narrow therapeutic index, adverse effects, and drug interactions. For older adults, another advice article names inhaled anticholinergics such as ipratropium bromide or tiotropium, along with short-acting beta-2 agonists, as safer first-line options.
The Bottom Line: Is Theophylline Right for You?
While the study didn't yield definitive proof, it does suggest theophylline might offer some benefits for certain COPD patients already using combination inhalers. Specifically, the improvements in exercise capacity were of high interest. Larger trials are necessary to confirm this, as well as assess the likelihood of any adverse effects.
Reassessing a Long-Used Treatment
A 2006 meta-analysis examined oral theophylline versus placebo in people with stable COPD. It included published trials that measured pulmonary function before and after theophylline treatment. A separate expert opinion focuses on reevaluating controlled-release theophylline for COPD and asthma in India, where both are described as leading chronic respiratory disorders contributing to morbidity and mortality.
Potential Directions for Future Research
A market report identifies integration into combination therapies, digital health monitoring, and personalized medicine as potential factors in theophylline’s long-term growth outlook. It describes these as future growth factors rather than established clinical developments. A 2023 review characterizes theophylline as an oral methylxanthine bronchodilator used as alternate therapy for asthma and COPD, while noting that it is not generally recommended.
Uncertainty About Add-On Risks
For people with stable COPD already receiving inhaled therapy, it remains unclear whether adding oral theophylline increases adverse reactions. A 2025 meta-analysis was conducted to systematically evaluate the effects of this add-on approach and provide a reference for clinical treatment. The source identifies this safety question as unresolved.
Reported Outcomes Over 12 Months
A prospective observational study reported that adjunctive low-dose theophylline in COPD management over 12 months was associated with significant improvements in lung function, symptom burden, and exacerbation rates. The study authors linked these findings to the drug’s potential anti-inflammatory and immunomodulatory effects. Because the evidence described here comes from an observational study, it reports outcomes in the studied patients rather than establishing that theophylline caused the improvements.
The researchers propose that a larger study, with 45 subjects in each arm, would be needed to detect a significant change in exercise duration. More research would also clarify which COPD patients are most likely to benefit from the medication.
If you're living with COPD and still experiencing limitations despite using inhalers, discuss these findings with your doctor. Theophylline might be a potential add-on therapy, but it's crucial to weigh the potential benefits against the risks and consider your individual circumstances. Don't make any changes to your treatment plan without professional medical advice.